OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Safety, tolerability, and efficacy of NLY01 in early untreated Parkinson's disease: a randomised, double-blind, placebo-controlled trial
Andrew McGarry, Shane Rosanbalm, Mika Leinonen, et al.
The Lancet Neurology (2023) Vol. 23, Iss. 1, pp. 37-45
Closed Access | Times Cited: 50
Andrew McGarry, Shane Rosanbalm, Mika Leinonen, et al.
The Lancet Neurology (2023) Vol. 23, Iss. 1, pp. 37-45
Closed Access | Times Cited: 50
Showing 1-25 of 50 citing articles:
Trial of Lixisenatide in Early Parkinson’s Disease
Wassilios G. Meissner, Philippe Rémy, Caroline Giordana, et al.
New England Journal of Medicine (2024) Vol. 390, Iss. 13, pp. 1176-1185
Closed Access | Times Cited: 117
Wassilios G. Meissner, Philippe Rémy, Caroline Giordana, et al.
New England Journal of Medicine (2024) Vol. 390, Iss. 13, pp. 1176-1185
Closed Access | Times Cited: 117
Efficacy and Safety of GLP-1 Medicines for Type 2 Diabetes and Obesity
Daniel J. Drucker
Diabetes Care (2024)
Open Access | Times Cited: 72
Daniel J. Drucker
Diabetes Care (2024)
Open Access | Times Cited: 72
Glucagon-like peptide-1 class drugs show clear protective effects in Parkinson's and Alzheimer's disease clinical trials: A revolution in the making?
Christian Hölscher
Neuropharmacology (2024) Vol. 253, pp. 109952-109952
Open Access | Times Cited: 19
Christian Hölscher
Neuropharmacology (2024) Vol. 253, pp. 109952-109952
Open Access | Times Cited: 19
Exenatide once a week versus placebo as a potential disease-modifying treatment for people with Parkinson's disease in the UK: a phase 3, multicentre, double-blind, parallel-group, randomised, placebo-controlled trial
Nirosen Vijiaratnam, Christine Girges, Grace Auld, et al.
The Lancet (2025)
Open Access | Times Cited: 2
Nirosen Vijiaratnam, Christine Girges, Grace Auld, et al.
The Lancet (2025)
Open Access | Times Cited: 2
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and suicidality: what do we know and future vistas
Roger S. McIntyre
Expert Opinion on Drug Safety (2024) Vol. 23, Iss. 5, pp. 539-542
Open Access | Times Cited: 13
Roger S. McIntyre
Expert Opinion on Drug Safety (2024) Vol. 23, Iss. 5, pp. 539-542
Open Access | Times Cited: 13
Dopamine Pharmacodynamics: New Insights
Fulvio Lauretani, Francesco Giallauria, Crescenzo Testa, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 10, pp. 5293-5293
Open Access | Times Cited: 10
Fulvio Lauretani, Francesco Giallauria, Crescenzo Testa, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 10, pp. 5293-5293
Open Access | Times Cited: 10
Type 2 diabetes mellitus/obesity drugs: A neurodegenerative disorders savior or a bridge too far?
Katherine O. Kopp, Elliot J. Glotfelty, Yazhou Li, et al.
Ageing Research Reviews (2024) Vol. 98, pp. 102343-102343
Closed Access | Times Cited: 8
Katherine O. Kopp, Elliot J. Glotfelty, Yazhou Li, et al.
Ageing Research Reviews (2024) Vol. 98, pp. 102343-102343
Closed Access | Times Cited: 8
GLP-1 programs the neurovascular landscape
Bandy Chen, Xiaofei Yu, Claudia Horvath-Diano, et al.
Cell Metabolism (2024) Vol. 36, Iss. 10, pp. 2173-2189
Closed Access | Times Cited: 8
Bandy Chen, Xiaofei Yu, Claudia Horvath-Diano, et al.
Cell Metabolism (2024) Vol. 36, Iss. 10, pp. 2173-2189
Closed Access | Times Cited: 8
Role of glucagon-like peptide-1 receptor agonists in Alzheimer’s disease and Parkinson’s disease
Chien‐Tai Hong, Jia‐Hung Chen, Chaur‐Jong Hu
Journal of Biomedical Science (2024) Vol. 31, Iss. 1
Open Access | Times Cited: 8
Chien‐Tai Hong, Jia‐Hung Chen, Chaur‐Jong Hu
Journal of Biomedical Science (2024) Vol. 31, Iss. 1
Open Access | Times Cited: 8
Are glucagon-like-peptide-1 (GLP-1) receptor agonists useful in treating Parkinson’s disease (PD). Does the clinical trial with lixisenatide add anything?
Sheila A Doggrell
Expert Opinion on Investigational Drugs (2025)
Closed Access | Times Cited: 1
Sheila A Doggrell
Expert Opinion on Investigational Drugs (2025)
Closed Access | Times Cited: 1
Some Novel Therapies in Parkinson’s Disease: A Promising Path Forward or Not Yet? A Systematic Review of the Literature
Anastasia Bougea
Biomedicines (2024) Vol. 12, Iss. 3, pp. 549-549
Open Access | Times Cited: 7
Anastasia Bougea
Biomedicines (2024) Vol. 12, Iss. 3, pp. 549-549
Open Access | Times Cited: 7
GLP-1, Parkinson’s Disease, and Neuroprotection
David G. Standaert
New England Journal of Medicine (2024) Vol. 390, Iss. 13, pp. 1233-1234
Closed Access | Times Cited: 5
David G. Standaert
New England Journal of Medicine (2024) Vol. 390, Iss. 13, pp. 1233-1234
Closed Access | Times Cited: 5
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and suicidality: A replication study using reports to the World Health Organization pharmacovigilance database (VigiBase®)
Roger S. McIntyre, Rodrigo B. Mansur, Joshua D. Rosenblat, et al.
Journal of Affective Disorders (2024)
Open Access | Times Cited: 5
Roger S. McIntyre, Rodrigo B. Mansur, Joshua D. Rosenblat, et al.
Journal of Affective Disorders (2024)
Open Access | Times Cited: 5
Disease-Modifying Therapies in Parkinson’s Disease
Margherita Fabbri, Jean‐Christophe Corvol, Olivier Rascol
Neurologic Clinics (2025) Vol. 43, Iss. 2, pp. 319-340
Closed Access
Margherita Fabbri, Jean‐Christophe Corvol, Olivier Rascol
Neurologic Clinics (2025) Vol. 43, Iss. 2, pp. 319-340
Closed Access
An update on drug repurposing in Parkinson’s disease: Preclinical and clinical considerations
Michela Salvadè, Mónica Di Luca, Fabrizio Gardoni
Biomedicine & Pharmacotherapy (2025) Vol. 183, pp. 117862-117862
Closed Access
Michela Salvadè, Mónica Di Luca, Fabrizio Gardoni
Biomedicine & Pharmacotherapy (2025) Vol. 183, pp. 117862-117862
Closed Access
Impact of diabetes mellitus type two on incidence and progression of Parkinson’s disease: a systematic review of longitudinal patient cohorts
Olga Stockmann, Lan Ye, Stephan Greten, et al.
Journal of Neural Transmission (2025)
Open Access
Olga Stockmann, Lan Ye, Stephan Greten, et al.
Journal of Neural Transmission (2025)
Open Access
Trends in mortality and disparities in dilated cardiomyopathy across gender, race, and region in the United States (1999-2020)
T Ashraf, Omar Abunada, Aashish Kumar, et al.
Annals of Medicine and Surgery (2025) Vol. 87, Iss. 3, pp. 1589-1598
Open Access
T Ashraf, Omar Abunada, Aashish Kumar, et al.
Annals of Medicine and Surgery (2025) Vol. 87, Iss. 3, pp. 1589-1598
Open Access
Vers un traitement neuroprotecteur dans la MPI ? La cible GLP-1
Wassilios G. Meissner
Pratique Neurologique - FMC (2025)
Closed Access
Wassilios G. Meissner
Pratique Neurologique - FMC (2025)
Closed Access
Semaglutide Ameliorates Neuroinflammation Caused by Enterogenous Pyrogen in APP/PS1 Mice
Yuan Yuan, Jiawei Zhang, Ziyao Zhang, et al.
Research Square (Research Square) (2025)
Closed Access
Yuan Yuan, Jiawei Zhang, Ziyao Zhang, et al.
Research Square (Research Square) (2025)
Closed Access
Morbus Parkinson: Neue GLP-1-Rezeptor-Agonisten-Variante auf dem Prüfstand
Neurologie up2date (2025) Vol. 08, Iss. 01, pp. 4-6
Closed Access
Neurologie up2date (2025) Vol. 08, Iss. 01, pp. 4-6
Closed Access
Efficacy and safety of GLP-1 agonists in Parkinson’s disease: a systematic review and meta-analysis of randomized controlled trials
Mark Messak, Ahmed Abdelmageed, Amira Senbel, et al.
Naunyn-Schmiedeberg s Archives of Pharmacology (2025)
Open Access
Mark Messak, Ahmed Abdelmageed, Amira Senbel, et al.
Naunyn-Schmiedeberg s Archives of Pharmacology (2025)
Open Access
The Gut‐Brain Axis in Parkinson disease: Emerging Concepts and Therapeutic Implications
Elisa Menozzi, Anthony H.V. Schapira, Per Borghammer
Movement Disorders Clinical Practice (2025)
Open Access
Elisa Menozzi, Anthony H.V. Schapira, Per Borghammer
Movement Disorders Clinical Practice (2025)
Open Access
Conversion between NMSS and MDS ‐NMS in Parkinson's Disease
Michela Garon, José‐Manuel Rojo‐Albuin, К. Ray Chaudhuri, et al.
Movement Disorders (2025)
Closed Access
Michela Garon, José‐Manuel Rojo‐Albuin, К. Ray Chaudhuri, et al.
Movement Disorders (2025)
Closed Access
Prevalence and risk factors of gross neurologic deficits in children after severe malaria: a systematic review protocol
Allen Eva Okullo, Chandy C. John, Richard Idro, et al.
Systematic Reviews (2025) Vol. 14, Iss. 1
Open Access
Allen Eva Okullo, Chandy C. John, Richard Idro, et al.
Systematic Reviews (2025) Vol. 14, Iss. 1
Open Access
The pharmacodynamics-based prophylactic benefits of GLP-1 receptor agonists and SGLT2 inhibitors on neurodegenerative diseases: evidence from a network meta-analysis
Ping‐Tao Tseng, Bing‐Yan Zeng, Chih-Wei Hsu, et al.
BMC Medicine (2025) Vol. 23, Iss. 1
Open Access
Ping‐Tao Tseng, Bing‐Yan Zeng, Chih-Wei Hsu, et al.
BMC Medicine (2025) Vol. 23, Iss. 1
Open Access
